The effect of astaxanthin supplementation on cytokeratin 18 levels

Phase 3

• Conditions: on alcoholic fatty liver.; Fatty (change of) liver, not elsewhere classified; K76.0

• Registration Number: IRCT20170628034786N3
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 May 2021

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 58

Inclusion Criteria

Children with non- alcoholic fatty liver disease
Age between 8-18 years old
Elevation of liver enzyme more than 40 Unit/Litre
Evidence of fatty liver in sonography

Exclusion Criteria

Diagnosis of liver disease other than NAFLD such as : Viral hepatitis,Autoimmune hepatitis, Diabetes, Hemochromatosis, Cirrhosis, Infectious disease, Hypothyroidism
Consumption of drugs that effect on liver enzyme during last two months
Alcohol consumption
Discontinuing the study by the patient or his/her family

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum level of Alanine aminotransferase. Timepoint: Eight weeks after treatment initiation with placebo and astaxanthin. Method of measurement: Quantitative measurement of liver transaminase.;Serum level of Aspartate aminotransferase. Timepoint: Eight weeks after treatment initiation with placebo and astaxanthin. Method of measurement: Quantitative measurement of liver transaminase.;Serum levels of cytokeratin 18. Timepoint: Eight weeks after treatment initiation with placebo and astaxanthin. Method of measurement: Eliza method.